# 2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma

> **NCT01353755** · PHASE3 · COMPLETED · sponsor: **Allergopharma GmbH & Co. KG** · enrollment: 195 (actual)

## Conditions studied

- Rhinoconjunctivitis
- Allergic Asthma

## Interventions

- **DRUG:** Grass pollen specific immunotherapy
- **DRUG:** Placabo

## Key facts

- **NCT ID:** NCT01353755
- **Lead sponsor:** Allergopharma GmbH & Co. KG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2012-08
- **Final completion:** 2014-09
- **Target enrollment:** 195 (ACTUAL)
- **Last updated:** 2014-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01353755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01353755, "2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01353755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*